Literature DB >> 17057197

Role of CEACAM1 as a regulator of T cells.

Takashi Nagaishi1, Hideki Iijima, Atsushi Nakajima, Daohong Chen, Richard S Blumberg.   

Abstract

A major immunological attribute of inflammatory bowel disease (IBD) is the presence of unrestrained activation of T cells that produce a variety of inflammatory cytokines and other mediators. Gaining an understanding of T cell regulation is therefore of major importance to IBD. Carcinoembryonic antigen-related cell adhesion molecule 1 CEACAM1) is a novel protein that has been recently recognized as being expressed by immune cells and T lymphocytes, in particular; this protein appears to function as a coinhibitory receptor after T cell activation. Ligation of CEACAM1 on T cells induces a signal cascade that leads inhibition of T cell cytokine production and IBD. CEACAM1 is thus a novel potential therapeutic target in the treatment of IBD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17057197     DOI: 10.1196/annals.1326.004

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

1.  The possible roles of OPN-regulated CEACAM1 expression in promoting the survival of activated T cells and the apoptosis of oral keratinocytes in oral lichen planus patients.

Authors:  Gui-Xiang Liu; Qi Xie; Cheng-Jun Zhou; Xiao-Ying Zhang; Bo-Long Ma; Cheng-Qin Wang; Feng-Cai Wei; Xun Qu; Shan-Zhen Sun
Journal:  J Clin Immunol       Date:  2011-06-14       Impact factor: 8.317

Review 2.  CEACAM1 structure and function in immunity and its therapeutic implications.

Authors:  Walter M Kim; Yu-Hwa Huang; Amit Gandhi; Richard S Blumberg
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

Review 3.  CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH).

Authors:  Sonia M Najjar; Lucia Russo
Journal:  Semin Immunopathol       Date:  2013-11-21       Impact factor: 9.623

4.  Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression.

Authors:  Kiera L Clayton; Matthew B Douglas-Vail; A K M Nur-ur Rahman; Karyn E Medcalf; Irene Y Xie; Glen M Chew; Ravi Tandon; Marion C Lanteri; Philip J Norris; Steven G Deeks; Lishomwa C Ndhlovu; Mario A Ostrowski
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

Review 5.  SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.

Authors:  Ulrike Lorenz
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

6.  Generation of human CEACAM1 transgenic mice and binding of Neisseria Opa protein to their neutrophils.

Authors:  Angel Gu; Zhifang Zhang; Nan Zhang; Walter Tsark; John E Shively
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

7.  Direct interaction of tumor suppressor CEACAM1 with beta catenin: identification of key residues in the long cytoplasmic domain.

Authors:  Lan Jin; Yun Li; Charng-Jui Chen; Mark A Sherman; Keith Le; John E Shively
Journal:  Exp Biol Med (Maywood)       Date:  2008-04-29

8.  Differential cell fates induced by all-trans retinoic acid-treated HL-60 human leukemia cells.

Authors:  Munetaka Ozeki; John E Shively
Journal:  J Leukoc Biol       Date:  2008-06-13       Impact factor: 4.962

9.  CEACAM6 gene variants in inflammatory bowel disease.

Authors:  Jürgen Glas; Julia Seiderer; Christoph Fries; Cornelia Tillack; Simone Pfennig; Maria Weidinger; Florian Beigel; Torsten Olszak; Ulrich Lass; Burkhard Göke; Thomas Ochsenkühn; Christiane Wolf; Peter Lohse; Bertram Müller-Myhsok; Julia Diegelmann; Darina Czamara; Stephan Brand
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Increased CD4(+) T cell co-inhibitory immune receptor CEACAM1 in neonatal sepsis and soluble-CEACAM1 in meningococcal sepsis: a role in sepsis-associated immune suppression?

Authors:  Michiel van der Flier; Dyana B Sharma; Silvia Estevão; Marieke Emonts; Denise Rook; Jan A Hazelzet; Johannes B van Goudoever; Nico G Hartwig
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.